Therapeutic Approaches and Clinical Outcomes of Myeloid/Lymphoid Neoplasms With Eosinophilia Harboring FLT3 Rearrangements: A Systematic Review of 39 Cases.
Peng Fang, Peng Zhang, Fan Yang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined treatment approaches and outcomes in 39 reported cases of myeloid/lymphoid neoplasms with eosinophilia harboring FLT3 rearrangements, a rare malignancy without standardized treatment guidelines. The review identifies hematopoietic stem cell transplantation (HSCT) as the central approach for long-term survival and a potentially curative option. Tyrosine kinase inhibitors (TKIs) were described as useful bridging therapy to transplantation, while TKI-based regimens with chemotherapy were proposed for patients unable to undergo HSCT. Chemotherapy alone was associated with uniformly poor outcomes in the reviewed cases.
Key findings
- The systematic review included 39 cases of FLT3-rearranged myeloid/lymphoid neoplasms with eosinophilia.
- HSCT was identified as the cornerstone for long-term survival and a potentially curative intervention.
- TKIs may serve as bridging therapy to HSCT by inducing remission and reducing tumor burden.
- For patients ineligible for HSCT, TKI-based regimens with chemotherapy were proposed; chemotherapy alone was associated with uniformly poor outcomes.
Why it matters
The review offers a treatment framework for a rare malignancy in which standardized guidelines are lacking. It highlights the potential role of transplantation and TKIs while distinguishing these approaches from chemotherapy alone, which had poor outcomes in the cases reviewed. These findings may help inform clinical decisions, although the evidence base remains limited to reported cases.
What to keep in mind
The evidence is based on a systematic review of only 39 reported cases, limiting the strength of treatment comparisons.